Seller record · remedymeds.com

Remedy Meds

Recorded September 2026 · Standard v1.1

Fails 4 of 8 criteria. S3, pharmacy identification: Eight pages were read, covering the terms, privacy, telehealth consent, safety, careers and footer surfaces, and each names only licensed United States pharmacies as a category. 3 more criteria also fail; see the table below.

Telehealth service. Passes 4 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling compounded semaglutide and tirzepatide on a membership that bundles medication with clinician access. It prints no price on any public page, and the street address it withholds appears in the FDA letter addressed to it.

Operating entity Remedy Meds LLC

Dispositions

Code	Criterion	Disposition	Where it was read
S1	Prescriber requirement	PASS	remedymeds.com/legal/terms-of-service
S2	Prescription gating	PASS	remedymeds.com/quiz
S3	Pharmacy identification	FAIL	remedymeds.com/legal/privacy-policy
S4	Compounding disclosure	PASS	remedymeds.com
S5	Analytical documentation	FAIL	remedymeds.com
S6	Business address	FAIL	remedymeds.com/legal/terms-of-service
S7	Price disclosure	FAIL	remedymeds.com/quiz
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

What was read, where, and on what date, for each disposition in the table above.

S1PASSThe terms state that medical evaluation, diagnosis, treatment decisions and prescribing are provided solely by licensed clinicians through the professional entities.Source: remedymeds.com/legal/terms-of-service.

S2PASSThe order path was walked through nine screens of health questions covering goals, height, weight, pace and eligibility, with no product page and no payment field.Source: remedymeds.com/quiz.

S3FAILEight pages were read, covering the terms, privacy, telehealth consent, safety, careers and footer surfaces, and each names only licensed United States pharmacies as a category.Source: remedymeds.com/legal/privacy-policy.

S4PASSThe homepage disclosure states that the products are compounded and that the Food and Drug Administration has not evaluated them for safety, quality or efficacy.Source: remedymeds.com.

S5FAILThe homepage prints four named tests marked passed, covering potency, sterility, pH and endotoxicity, and it names no laboratory, no lot and no document.Source: remedymeds.com.

S6FAILEight pages were read, covering footer, terms, privacy, telehealth consent, safety and careers, and the only contact details printed are a telephone number and an email address.Source: remedymeds.com/legal/terms-of-service.

S7FAILNo price appears on any of the eight pages read, and none appeared across the nine intake screens walked before the eligibility questions.Source: remedymeds.com/quiz.

S8PASSFDA warning letter 716830, September 2025, names Remedy Meds at a Summit, New Jersey street address the site itself does not publish, and cites claims of the same active ingredient as an approved drug. No FDA action has halted the business, and the seller still trades.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide.

Enforcement documents on file: 1 warning letter

FDA warning letter 716830, issued September 2025, to Remedy MedsClaims on remedymeds.com that compounded semaglutide and tirzepatide are the same active ingredient as four approved brands are false or misleading.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.